News

Nectero Medical Secures Category III CPT Codes for Investigational Therapy to Treat Small- to Medium-Sized AAAs

Milestone paves the way for future reimbursement of the Nectero EAST® SystemTEMPE, Az., June 12, 2025 (GLOBE NEWSWIRE) -- Nectero…

7 months ago

Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML)

Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025…

7 months ago

DiagnaMed Appoints John Karagiannidis as President & CEO; Fabio Chianelli Transitions to Director Role Strengthening Strategic Partnership with QIMC to Accelerate Natural Hydrogen Development in Ontario

TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("”DiagnaMed” or “DMED") (CSE: DMED) (OTCQB: DGNMF), a Canadian technology…

7 months ago

Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML)

Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025…

7 months ago

Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML)

Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025…

7 months ago

DiagnaMed Appoints John Karagiannidis as President & CEO; Fabio Chianelli Transitions to Director Role Strengthening Strategic Partnership with QIMC to Accelerate Natural Hydrogen Development in Ontario

TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("”DiagnaMed” or “DMED") (CSE: DMED) (OTCQB: DGNMF), a Canadian technology…

7 months ago

Werewolf Therapeutics to Participate in the BIO International Convention

WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical…

7 months ago

Werewolf Therapeutics to Participate in the BIO International Convention

WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical…

7 months ago

Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335

Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected…

7 months ago

Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335

Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected…

7 months ago
Show more Posts
Show previous Posts